Life sciences and healthcare recruiting in Japan
Life sciences and healthcare is the third-largest hiring vertical for English-speaking recruiting in Japan, after financial services and technology. Seventeen of the thirty-one firms in this directory operate active life sciences desks. The vertical is structurally distinctive on two dimensions. First, the bilingual constraint is more binding than in any other vertical: regulatory affairs, medical affairs, and clinical operations require Japanese fluency combined with deep technical or medical English, and the bilingual cohort is in the low hundreds nationally for the senior end of these functions. Second, the geographic footprint extends beyond Tokyo: Tsukuba Science City and the Kansai R&D cluster (Osaka, Suita, Kobe) are material centres of pharma research employment that other verticals largely do not encounter.
This page maps which firms cover what, organised by factual characteristic rather than by editorial ranking. The directory does not claim a "best" firm in any vertical. The right firm depends on the role's seniority, the firm's hiring model preference, the candidate's bilingual profile, and whether the client is a foreign-capital pharma, a Japanese-domiciled pharma, a medical device company, a CRO/CDMO, or a digital health entrant.
What this vertical covers
The life sciences hiring market in Japan splits into ten distinguishable sub-verticals.
Pharma R&D — drug discovery, preclinical, translational research, computational chemistry, biology, pharmacology. Japanese pharma R&D is concentrated at Astellas (Tsukuba), Daiichi Sankyo (Shinagawa and Tsukuba), Takeda (Osaka — Shonan iPark — and Cambridge, MA), Chugai (Roche group, Kamakura), Eisai (Tsukuba), Sumitomo Pharma (Suita), Otsuka (Tokushima R&D, Tokyo HQ), and Shionogi (Toyonaka). Foreign pharma R&D presence in Japan is smaller but exists at Roche/Chugai, Pfizer, Novartis, AstraZeneca, MSD, GSK, and Eli Lilly. Coverage at Real Staffing, Apex, Brunel, Robert Walters, JAC Recruitment, en world, and the retained firms for senior R&D leadership.
Clinical operations and trials — clinical research associates (CRA), clinical trial managers (CTM), study managers, biostatisticians, data managers, clinical pharmacology, regulatory CMC. Both Japanese pharma and foreign-CRO operations in Japan hire heavily in this segment. Coverage at Real Staffing, Apex, Robert Walters, Hays Japan, JAC Recruitment, en world, and Brunel.
Regulatory affairs — PMDA filings (NDA, sNDA, MAA, JNDA), MHLW interactions, post-marketing surveillance, GVP/GCP compliance. The single most bilingual-constrained sub-segment in life sciences. Coverage at Real Staffing, Apex, Robert Walters, JAC Recruitment, and en world. Senior regulatory leadership is retained at the Big 4 and Boyden.
Medical affairs — Medical Science Liaison (MSL), Medical Advisor, Medical Director, scientific communication, medical information, KOL engagement. Bilingual MD/PhD pool is small. Coverage at Real Staffing, Apex, Robert Walters, JAC Recruitment, and en world; senior medical affairs (Therapeutic Area Lead, Country Medical Director) is predominantly retained.
Commercial — pharma sales, marketing, market access — MR (Medical Representative — certified through 公益財団法人MR認定センター), product manager, brand manager, market access manager, KAM, payer engagement. In the directory's reported data, the largest sub-vertical by headcount but increasingly under pressure as the MR-driven model evolves toward digital and KAM. Coverage at Real Staffing, Apex, Robert Walters, Hays Japan, JAC Recruitment, en world, RGF, and Randstad.
Medical devices — sales, marketing, clinical specialists, regulatory, QA, R&D. Foreign device firms in Japan (J&J Medtech, Medtronic, Stryker, Boston Scientific, Abbott, Edwards Lifesciences, BD, Bausch & Lomb) plus Japanese device companies (Olympus, Terumo, Nipro, Hoya, Nikon medical) are the primary clients. Coverage at Real Staffing, Apex, Robert Walters, Hays Japan, JAC Recruitment, en world, RGF, and Brunel for the engineering side.
Biotech — biotech-specific R&D, business development, clinical, regulatory at biotech-stage companies. The Japanese biotech ecosystem includes Astellas Innovation Lab, Takeda Vaccine, biotech-stage subsidiaries of the Big 7, and a smaller startup set (PeptiDream, JCR Pharmaceuticals, So-Pharma, Healios). Foreign biotech presence is concentrated at Moderna Japan, BioNTech Japan, and via larger pharma's biotech-acquired pipelines. Coverage overlaps heavily with pharma R&D and at the Big 4 retained firms.
Diagnostics — in vitro diagnostics (IVD), companion diagnostics, molecular diagnostics, clinical chemistry. Roche Diagnostics (Yokohama), Abbott Diagnostics, Beckman Coulter, Siemens Healthineers, plus Japanese (Sysmex in Kobe, Sekisui Medical, FUJIFILM Diagnostics). Coverage at Real Staffing, Apex, Robert Walters, JAC Recruitment, and en world.
Digital health and healthtech — telemedicine platforms, electronic health records, AI-driven diagnostics, healthcare data analytics. M3 (TSE), JMDC, Ubie, MICIN, MedPeer, plus the Japan operations of foreign healthtech (Doximity-equivalent and EHR vendors). Bilingual product, engineering, and commercial roles. Coverage overlaps with Technology vertical — Build+ and the tech specialists also touch this segment.
CRO and CDMO services — contract research organisations (clinical operations services to pharma) and contract development and manufacturing organisations (manufacturing services). Foreign CROs in Japan: IQVIA, Parexel, Labcorp/Covance, ICON, PPD/Thermo Fisher, Syneos Health. Japanese CROs: CMIC Holdings, Linical, EPS Holdings, ACRO. CDMOs: Lonza Tokyo, Catalent Japan, Samsung Biologics, AGC Biologics, Asahi Kasei Pharmaceuticals. Coverage at Real Staffing, Apex, Robert Walters, JAC Recruitment, en world, and Brunel.
Firms covering this vertical, organised by characteristic
The 17 firms with active life sciences desks fall into five groups.
1. Life-sciences-specialist firms
Firms whose Japan operation includes a substantial life-sciences-specialist practice.
- Real Staffing Japan — life sciences specialist contingency recruiter; Japan trading division of SThree K.K. (LSE: STEM parent); shares the Ginza Kabukiza Tower office with sister SThree brands (Computer Futures, Huxley, Progressive, Global Enterprise Partners).
- Apex K.K. — bilingual executive search firm founded in Tokyo in 2010 by five executive recruiters; healthcare-roots that have expanded to 11 specialist teams; member of the Kestria global alliance; ~110+ employees in Ebisu.
- Brunel Japan — engineering, energy, and life sciences staffing firm; Japan entity established 2009 in Shibuya as a fully licensed subsidiary of Brunel International (Euronext: BRNL).
2. Generalist UK-listed contingency-led firms with life sciences desks
Multi-vertical firms whose life sciences desks are material Japan practices.
- Robert Walters Japan K.K. — UK-listed (LSE: RWA); Tokyo since January 2000.
- Hays Specialist Recruitment Japan K.K. — FTSE 250-listed (LSE: HAS); Tokyo office since 2001.
3. TSE-listed Japan-headquartered bilingual firms
Firms whose parent is listed on the Tokyo Stock Exchange and whose primary clients include both foreign-capital and Japanese-domiciled pharma and device companies.
- JAC Recruitment Co., Ltd. — TSE Prime: 2124; founded in London 1975, entered Japan 1988; group HQ since 2006 IPO.
- en world Japan K.K. — Tokyo-headquartered, founded 1999; joined the en-japan group (TSE Prime: 4849) in 2010; reports working with ~87% of the ~3,200 foreign-capital firms in Japan.
- RGF Professional Recruitment / RGF Executive Search Japan — bilingual executive search firm founded 1998. As of April 1, 2026, a Fullcast Holdings (TSE: 4848) subsidiary following Recruit Holdings' divestiture of its international recruitment business.
4. Global retained executive search
Retained firms covering Country Medical Director, Country General Manager, VP Commercial, Head of R&D Japan, Head of Regulatory Affairs, and board-level mandates across pharma, biotech, and devices.
- Korn Ferry Japan — NYSE-listed (KFY); Tokyo office since 1973 in Marunouchi Trust Tower.
- Heidrick & Struggles Japan — private since Dec 2025; formerly NASDAQ: HSII; Tokyo office in Atago Green Hills MORI Tower.
- Spencer Stuart Japan — privately held; Tokyo office serving Japan's largest companies on board and CEO mandates.
- Russell Reynolds Japan — privately held; Tokyo office since the mid-1980s.
- Egon Zehnder Tokyo — privately held; Tokyo office (1972) was the firm's first non-European location; Kyoto office opened 2026.
- Boyden Japan — global retained executive search firm with 75+ offices in 45+ countries; Tokyo office led by Stephen Irish (Managing Partner since 2021) with documented strength in healthcare and life sciences.
- Stanton Chase Tokyo — global retained executive search firm; Tokyo office joined the Stanton Chase group in 2000.
5. Mass-market and adjacent
- Randstad K.K. — Japanese subsidiary of Randstad N.V. (Euronext: RAND); 120+ branches nationwide; the Professionals (mid-career / executive search) division has been growing the bilingual life sciences practice since 2014.
Mentioned but distinct primary positioning
- Cornerstone Recruitment Japan K.K. — bilingual recruiter founded 2019 as a Tokyo joint venture of Cornerstone Global Partners (CGP) and Morgan Stanley; primary focus is financial services but the firm covers healthcare-investment-adjacent roles given the Morgan Stanley parent's healthcare investment banking practice.
Business models in this vertical
The same three engagement models documented for technology and financial services apply in life sciences, with two characteristic differences.
Contingency at IC and manager level (¥10–22M comp). The default model at all generalist firms (Robert Walters, Hays Japan), the specialists (Real Staffing, Apex's healthcare practice, Brunel), the TSE-listed bilinguals (JAC, en world, RGF), and Randstad. Reported fees in the 28–35% range, with regulatory affairs and medical affairs at the upper end given the bilingual scarcity.
Retained search at director, Country Medical Director, Country GM, and board level. The predominant model at the Big 4 (Korn Ferry, Heidrick & Struggles, Spencer Stuart, Russell Reynolds) plus Egon Zehnder, Boyden, and Stanton Chase. Boyden's Tokyo Managing Partner Stephen Irish has documented healthcare and life sciences focus that is publicly noted by the firm. Page Executive does not appear in the 17-firm life sciences set on this directory.
Clinical and CDMO contract staffing. Distinct from permanent placement. Brunel runs a meaningful clinical contracting practice in Japan; Real Staffing handles contract CRA and study coordinator placement for both foreign and Japanese CROs. The contract-staffing model is structurally important during clinical trial peak loads and during CDMO manufacturing campaigns.
A characteristic difference from the financial services and technology verticals: tenure at hiring companies in life sciences is materially longer than in tech. Bilingual MSLs at major foreign pharma operations frequently have 5–8 year tenures; senior regulatory affairs professionals often longer. This compresses transactional volume per candidate but creates higher-quality, longer-cycle recruiter relationships.
Recent market signals
These are the most recent confirmed signals from listed-parent disclosures and primary press relevant to Japanese life sciences hiring. For the full feed, see recruiters.fyi/news.
- Q1 2026 — Robert Walters plc: Japan net fees +13% YoY; life sciences is one of multiple Japan desks contributing to the recovery. Source: Robert Walters plc Q1 2026 trading update / LSE filings.
- Q3 FY2026 — Hays plc: Asia net fees +8% led by Japan +33%. Source: Hays plc Q3 FY2026 trading update.
- Q1 2026 — Robert Half: International staffing revenue +0.4% adjusted; Japan business is more weighted to financial services and IT than to life sciences. Source: Robert Half Q1 2026 results.
- April 2026 — RGF transition: RGF Professional Recruitment became a Fullcast Holdings (TSE: 4848) subsidiary effective April 1, 2026, following Recruit Holdings' divestiture of its international recruitment business; RGF's life sciences desk is part of the bilingual executive search practice retained under Fullcast. Source: Fullcast Holdings, Recruit Holdings public disclosures.
- 2026 — Egon Zehnder Kyoto office: Egon Zehnder opened a second Japan office in Kyoto in 2026 — the firm's second non-European city after the original 1972 Tokyo office; Kyoto is geographically aligned with Kansai pharma R&D (Takeda Shonan iPark, Sumitomo Pharma Suita, Otsuka Tokushima, Shionogi Toyonaka). Source: Egon Zehnder corporate communications.
- 2026 — Boyden Tokyo healthcare focus: Boyden Japan, under Managing Partner Stephen Irish, has reported continued specialisation in healthcare and life sciences leadership search since the 2021 leadership transition. Source: Boyden corporate communications.
Geographic concentration
Life sciences hiring in Japan has the most distributed geographic footprint of any vertical in this directory. Tokyo remains the centre of commercial, medical affairs, and senior leadership hiring — but R&D, clinical operations, and bio-manufacturing extend into Tsukuba, Yokohama, and the Kansai cluster.
Within Tokyo:
- Otemachi and Marunouchi — Astellas Pharma (Otemachi) and Daiichi Sankyo (Shinagawa-adjacent); Korn Ferry (Marunouchi Trust Tower) and the foreign-capital pharma offices clustered nearby.
- Hibiya and Toranomon — Takeda Global Headquarters (Hibiya); foreign pharma offices in Toranomon (Bayer, MSD).
- Roppongi and Akasaka — AstraZeneca, GSK, AbbVie, BMS, and several smaller foreign pharma offices.
- Shinjuku — Roche/Chugai (Shinjuku Mitsui Building), Eli Lilly Japan, Pfizer Japan.
- Shibuya — digital health cluster (M3, Ubie, MICIN, JMDC); some bilingual healthtech overlap with the Technology vertical recruiters.
- Shinagawa — Daiichi Sankyo R&D; some device companies.
- Ginza and Yurakucho — Real Staffing (Ginza Kabukiza Tower).
- Ebisu — Apex.
- Akihabara and Kanda — LHH (Akihabara UDX Building); some clinical-tech adjacency.
Outside Tokyo:
- Tsukuba Science City (Ibaraki) — Astellas R&D, Eisai R&D, plus government and academic research (RIKEN, AIST, JST). Geographic relocation barrier limits movement between Tokyo commercial and Tsukuba R&D — a structurally important constraint for recruiters covering the R&D function.
- Yokohama (Minato Mirai and Tsurumi) — Roche Diagnostics, Sony Healthcare adjacent businesses, some device R&D.
- Kansai (Osaka, Suita, Kobe, Toyonaka) — Takeda Shonan iPark and Osaka HQ, Sumitomo Pharma (Suita), Shionogi (Toyonaka), Otsuka (with Tokushima R&D), plus Sysmex (Kobe). Robert Walters, JAC Recruitment, Randstad, en world, and ManpowerGroup all maintain Osaka offices; the bilingual life sciences hiring concentration in Kansai is meaningfully larger than in any other vertical.
- Hyogo (Kobe Biomedical Innovation Cluster) — biomedical research and contract manufacturing; growing but small.
Hiring talent constraints specific to this vertical
Three constraints shape who gets hired and which firms place them in life sciences.
Bilingual + technical depth. The single largest constraint. Regulatory affairs, medical affairs, clinical operations at the senior end, and R&D leadership all require N1 Japanese plus deep technical or medical English. The bilingual cohort at the senior end of regulatory affairs is in the low hundreds nationally; for medical affairs at therapeutic-area-lead level it is similar. This narrowness creates structural fee resilience for firms with durable relationships to the small senior cohort.
MR certification and pharma sales structure. MR (Medical Representative) certification through the 公益財団法人MR認定センター is the standard credential for pharma sales in Japan. The MR pool has been gradually contracting since 2018 as foreign and Japanese pharma have shifted toward digital engagement and KAM models. Recruiters covering the commercial pharma sub-vertical operate in a contracting pool; the bilingual MR-to-KAM conversion has been a recurring movement pattern since 2020.
Geographic relocation barriers. Tsukuba and Kansai R&D require physical relocation; Tokyo-based bilingual R&D candidates frequently decline R&D-coded offers requiring relocation. This produces a structural preference for retained search engagements at R&D leadership level, where the recruiter is engaged on a defined set of relocation-willing or already-Tsukuba-based candidates.
Frequently asked questions
See the FAQ block in the page sidebar (rendered from the structured faqs: field) for full answers. Topics covered:
1. Which firms cover life sciences and healthcare recruiting in Japan?
2. Which firms specialize in pharma and biotech recruiting in Japan?
3. Which firms cover regulatory affairs hiring in Japan?
4. Which firms cover medical affairs and MSL hiring in Japan?
5. Which firms cover medical device hiring in Japan?
6. What's the typical placement fee for a life sciences hire in Japan?
7. Where are Tokyo's life sciences recruiters and clients based?
8. How does the bilingual constraint affect life sciences hiring?
9. Which firms cover CRO hiring in Japan?
10. Which firms place country medical directors and Japan GMs in pharma?
Related reading
- Contingency vs retained search in Japan
- What it costs to hire through a recruiter in Japan: placement fees explained
- Foreign-capital vs Japanese-domiciled recruiters in Japan
- Publicly-listed recruiting firms in Japan: LSE, NYSE, NASDAQ, TSE
- Adjacent vertical: Industrial / Manufacturing (for bio-manufacturing CDMOs)
- Adjacent vertical: Technology (for digital health)
- Adjacent vertical: Executive / Board / CEO
- Comparison: Computer Futures vs Global Enterprise Partners
- Comparison: Boyden vs Stanton Chase
Methodology
This page is built from the 17 individual firm profiles in the directory. Every firm-level claim links to the underlying profile, where the primary source is documented. Structural claims about the vertical (sub-vertical splits, geographic clustering, business model distribution) are synthesized across the corpus and labelled as synthesis in the section sourcing field. See editorial standards for the complete sourcing framework.
This page was last refreshed on 2026-05-03. Quick-facts items are re-verified quarterly. Material changes (M&A, listing changes, major firm transitions) trigger updates within seven days of public confirmation.